HLA-A24-binding KIF-derived peptide
US7968098B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2007 |
| Grant date | Jun 28, 2011 |
| Priority date | — |
| Expiry date | Apr 7, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.